Photo of Che-Kai Tsao

Che-Kai Tsao

  • ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
Print ProfilePrint Profile


  • Hematology

  • Medical Oncology

  • American Board of Internal Medicine


  • MD, SUNY Downstate Medical Center

  • Residency, Internal Medicine
    Long Island Jewish Medical Center

  • Fellowship, Hematology/Oncology
    Mount Sinai Hospital


    Che-Kai Tsao, MD is an Assistant Professor of Medicine, Hematology and Medical Oncology at the Tisch Cancer Institute, Mount Sinai Medical Center.

    Dr. Tsao's primary research interest is the development of novel therapies in the treatment of genitourinary cancers, including prostate, bladder, and kidney malignancies.


  • 2012 -
    Physician of the Year, Fellow Award
    Mount Sinai Hospital

  • 2012 -
    Merit Award
    American Society of Clinical Oncology

  • 2012 -
    GU Cancers Merit Award
    American Society of Clinical Oncology

  • 2011 -
    Oncology Trainee Travel Award
    American Society of Clinical Oncology

  • 2011 -
    Workshop on Methods in Clinical Cancer Research


Genitourinary Cancers

Prostate Cancer, Kidney Cancer, Bladder Cancer, Testicular Cancer, and Adrenal Cancer.


Tsao CK, Galsky MD, Oh WK. Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer. European urology 2014 Jan;.

Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Dec; 30(35).

Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. Journal of the National Cancer Institute 2012 Dec; 104(23).

Tsao CK, Oh WK. Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks. Nature reviews. Clinical oncology 2012 Nov; 9(11).

Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 2012 Jun;.

Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Current opinion in urology 2012 May; 22(3).

Tsao C, Galsky MD, Small AC, Yee T, Oh WK. Targeting the Androgen Receptor Signaling Axis in Castration Resistant Prostate Cancer. British Journal of Urology-International;.

Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clinical genitourinary cancer 2012 Mar; 10(1).

Tsao CK, Oh WK. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian journal of andrology 2011 Mar; 13(2).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Tsao during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • Amgen Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central

Ruttenberg Treatment Center

1470 Madison Avenue
3rd floor
New York, NY 10029

Tel: 212-241-6756
Fax: 212-659-5599
Get Directions

Office Hours:
  • Friday 9:00am - 1:00pm
  • Chinese (Mandarin)
  • Chinese (Other)
Insurance Plans
  • 1199
  • Access Medicare
  • Aetna
  • Affinity
  • Amerigroup
  • AmidaCare
  • Cigna
  • Empire Blue Cross/Blue Shield - PPO
  • Fidelis Care NY
  • GHI
  • Health Insurance Plan (HIP)
  • HealthFirst
  • Humana
  • Island Group
  • Magnacare
  • Medicaid of New York
  • Medicare
  • MetroPlus Health Plan
  • MultiPlan, Inc.
  • Oxford Health Plans
  • Pomco
  • United Healthcare
  • VNS Medicare
  • WellCare of New York, Inc.
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash

Mount Sinai Queens Cancer Program

27-15 30th Avenue
Astoria, NY 11102

Tel: 718-808-7372
Fax: 718-278-2941
Get Directions

Office Hours:
  • Monday 8:00am - 4:30pm
  • Tuesday 8:00am - 4:30pm
  • Wednesday 8:00am - 4:30pm
  • Thursday 8:00am - 4:30pm